JP2018537968A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537968A5 JP2018537968A5 JP2018522020A JP2018522020A JP2018537968A5 JP 2018537968 A5 JP2018537968 A5 JP 2018537968A5 JP 2018522020 A JP2018522020 A JP 2018522020A JP 2018522020 A JP2018522020 A JP 2018522020A JP 2018537968 A5 JP2018537968 A5 JP 2018537968A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- light chain
- antibody
- rabbit
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 16
- 230000009261 transgenic effect Effects 0.000 claims description 16
- 108060003951 Immunoglobulin Proteins 0.000 claims description 15
- 102000018358 immunoglobulin Human genes 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 108091026890 Coding region Proteins 0.000 claims description 6
- 108700019146 Transgenes Proteins 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 2
- 101150117115 V gene Proteins 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000004777 loss-of-function mutation Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15192002.2 | 2015-10-29 | ||
| EP15192002.2A EP3184547A1 (en) | 2015-10-29 | 2015-10-29 | Anti-tpbg antibodies and methods of use |
| EP16162580 | 2016-03-29 | ||
| EP16162580.1 | 2016-03-29 | ||
| PCT/EP2016/075882 WO2017072208A1 (en) | 2015-10-29 | 2016-10-27 | Transgenic rabbit with common light chain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537968A JP2018537968A (ja) | 2018-12-27 |
| JP2018537968A5 true JP2018537968A5 (enExample) | 2019-11-21 |
| JP7085992B2 JP7085992B2 (ja) | 2022-06-17 |
Family
ID=57233408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522020A Active JP7085992B2 (ja) | 2015-10-29 | 2016-10-27 | 共通軽鎖を有するトランスジェニックウサギ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230332175A1 (enExample) |
| EP (1) | EP3367786A1 (enExample) |
| JP (1) | JP7085992B2 (enExample) |
| CN (3) | CN113862300A (enExample) |
| HK (1) | HK1258306A1 (enExample) |
| SG (2) | SG10202006332PA (enExample) |
| WO (1) | WO2017072208A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3765493A2 (en) | 2018-03-12 | 2021-01-20 | Genmab A/S | Antibodies |
| US12467062B2 (en) | 2018-12-21 | 2025-11-11 | Compass Therapeutics Llc | Transgenic mouse expressing common human light chain |
| AU2021283564B2 (en) * | 2020-06-02 | 2025-05-29 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with common light chain immunoglobulin locus |
| WO2022095970A1 (zh) * | 2020-11-06 | 2022-05-12 | 百奥泰生物制药股份有限公司 | 双特异抗体及其应用 |
| CN115702931A (zh) * | 2021-08-06 | 2023-02-17 | 百奥泰生物制药股份有限公司 | 抗pd-l1/cd47双特异抗体在治疗疾病中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0979281B1 (en) * | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| JP5694623B2 (ja) * | 1999-02-05 | 2015-04-01 | セラピューティック ヒューマン ポリクローナルズ， インコーポレイテッド | 遺伝子操作した動物から得られるヒトポリクローナル抗体 |
| CA2634294A1 (en) * | 2000-08-03 | 2002-02-14 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
| MXPA06000562A (es) * | 2003-07-15 | 2006-03-30 | Therapeutic Human Polyclonals | Loci de inmunoglobulina humanizada. |
| JP2008517600A (ja) * | 2004-10-22 | 2008-05-29 | セラピューティック ヒューマン ポリクローナルズ， インコーポレイテッド | ヒト以外のトランスジェニック動物における内因性免疫グロブリン発現の抑制 |
| CN102443058A (zh) * | 2005-08-03 | 2012-05-09 | 人类多克隆治疗股份有限公司 | 表达人源化免疫球蛋白的转基因动物中b细胞凋亡的抑制 |
| WO2008027986A2 (en) * | 2006-09-01 | 2008-03-06 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| EA201001691A1 (ru) * | 2008-04-28 | 2011-10-31 | Калобайос Фармасьютикалз, Инк. | Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору |
| US20110152173A1 (en) * | 2008-07-02 | 2011-06-23 | Emergent Product Development Seattle ,LLC | TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS |
| SI2315777T1 (sl) * | 2008-07-08 | 2017-09-29 | Geneuro Sa | Terapevtska uporaba specifičnega liganda pri s msrv povezanih boleznih |
| WO2010032059A2 (en) * | 2008-09-19 | 2010-03-25 | Medimmune Llc | Targeted binding agents directed to cd105 and uses thereof |
| US20130045492A1 (en) * | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| JP6016800B2 (ja) * | 2010-12-15 | 2016-10-26 | ワイス・エルエルシー | 抗ノッチ１抗体 |
| ES2743399T3 (es) * | 2012-04-20 | 2020-02-19 | Merus Nv | Métodos y medios para la producción de moléculas heterodiméricas similares a Ig |
| WO2014022540A1 (en) * | 2012-08-02 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Multivalent antigen-binding proteins |
| US10358492B2 (en) * | 2012-09-27 | 2019-07-23 | Merus N.V. | Bispecific IgG antibodies as T cell engagers |
| AU2013396206B2 (en) * | 2013-06-28 | 2019-11-14 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
| PE20160953A1 (es) * | 2013-12-12 | 2016-09-26 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este |
| SG11201607109QA (en) * | 2014-02-28 | 2016-09-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
| US20170022291A1 (en) * | 2014-04-01 | 2017-01-26 | Adimab, Llc | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
-
2016
- 2016-10-27 CN CN202111174951.7A patent/CN113862300A/zh active Pending
- 2016-10-27 EP EP16790926.6A patent/EP3367786A1/en active Pending
- 2016-10-27 SG SG10202006332PA patent/SG10202006332PA/en unknown
- 2016-10-27 WO PCT/EP2016/075882 patent/WO2017072208A1/en not_active Ceased
- 2016-10-27 CN CN202111178978.3A patent/CN113897371A/zh active Pending
- 2016-10-27 CN CN201680063211.7A patent/CN108347906A/zh active Pending
- 2016-10-27 HK HK19100672.4A patent/HK1258306A1/zh unknown
- 2016-10-27 SG SG11201802698XA patent/SG11201802698XA/en unknown
- 2016-10-27 JP JP2018522020A patent/JP7085992B2/ja active Active
-
2022
- 2022-11-02 US US18/052,113 patent/US20230332175A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537968A5 (enExample) | ||
| JP2018138047A5 (enExample) | ||
| JP2020536532A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2020508655A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| JP2018046872A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2016512034A5 (enExample) | ||
| JP2011036254A5 (enExample) | ||
| JP2011182801A5 (enExample) | ||
| JP2018517431A5 (enExample) | ||
| JP2017504577A5 (enExample) | ||
| WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
| JP2014518615A5 (enExample) | ||
| JP2020517287A5 (enExample) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2018121657A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2017176174A5 (enExample) | ||
| JP2009539348A5 (enExample) | ||
| JP2018530331A5 (enExample) | ||
| JP2012502649A5 (enExample) | ||
| JP2010526028A5 (enExample) |